Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Ryan

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Expert Opinion on Investigational Drugs|March 16, 2010
Abiraterone acetate for castration resistant prostate cancerShreya Shah, Charles Ryan
Postgraduate Medicine|November 9, 2013
A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancerCharles Ryan, Neal D Shore, Raoul Concepcion
Prostate Cancer and Prostatic Diseases|December 18, 2019
A review of prostate cancer treatment impact on the CNS and cognitive functionCharles Ryan, Jeffrey S Wefel, Alicia K Morgans
The Oncologist|December 21, 2018
Recycling Discarded Drugs: Improving Access to Oral Antineoplastic DrugsJodi L Layton, Brian Lewis, Charles Ryan, et al.
Bioconjugate Chemistry|November 22, 2013
Synthesis and characterization of an anti-apoptotic immunosuppressive compound for improving the outcome of islet transplantationHao Wu, Jayaprakash Pagadala, Charles Ryan Yates, et al.
Ear, Nose, & Throat Journal|August 27, 2013
Middle ear effusion in adult ICU patients: a cohort studyBradley W Kesser, Charles Ryan Woodard, Nicholas G Stowell, et al.
Endocrine Oncology (Bristol, England)|July 12, 2023
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancerSean McSweeney, Hannah E Bergom, Anna Prizment, et al.
Anti-Cancer Drugs|December 18, 2009
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapyTomasz M Beer, Charles Ryan, Joshi Alumkal, et al.
The Journal of Urology|October 16, 2007
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancerMichael J Morris, W Kevin Kelly, Susan Slovin, et al.
Journal of Dietary Supplements|June 17, 2020
Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory ApproachesLarry A Walker, Igor Koturbash, Rick Kingston, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Expert Opinion on Investigational Drugs|March 16, 2010
Abiraterone acetate for castration resistant prostate cancerShreya Shah, Charles Ryan
Postgraduate Medicine|November 9, 2013
A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancerCharles Ryan, Neal D Shore, Raoul Concepcion
Prostate Cancer and Prostatic Diseases|December 18, 2019
A review of prostate cancer treatment impact on the CNS and cognitive functionCharles Ryan, Jeffrey S Wefel, Alicia K Morgans
The Oncologist|December 21, 2018
Recycling Discarded Drugs: Improving Access to Oral Antineoplastic DrugsJodi L Layton, Brian Lewis, Charles Ryan, et al.
Bioconjugate Chemistry|November 22, 2013
Synthesis and characterization of an anti-apoptotic immunosuppressive compound for improving the outcome of islet transplantationHao Wu, Jayaprakash Pagadala, Charles Ryan Yates, et al.
Ear, Nose, & Throat Journal|August 27, 2013
Middle ear effusion in adult ICU patients: a cohort studyBradley W Kesser, Charles Ryan Woodard, Nicholas G Stowell, et al.
Endocrine Oncology (Bristol, England)|July 12, 2023
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancerSean McSweeney, Hannah E Bergom, Anna Prizment, et al.
Anti-Cancer Drugs|December 18, 2009
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapyTomasz M Beer, Charles Ryan, Joshi Alumkal, et al.
The Journal of Urology|October 16, 2007
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancerMichael J Morris, W Kevin Kelly, Susan Slovin, et al.
Journal of Dietary Supplements|June 17, 2020
Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory ApproachesLarry A Walker, Igor Koturbash, Rick Kingston, et al.
Pageof 3